Our results imply that the beneficial therapeutic effects of PPAR agonists in patients with NAFLD may be attributed to reversing and normalizing levels of the relevant hepatic genes. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.